1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Precision System Science Co.,Ltd

Precision System Science Co.,Ltd

TTSE:7707
208.00
JPY
-2.00
(-0.95%)
6.36BMarket Cap
Nov 13Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
214.87
281.8
220.64
183.6
157.85
179.98
195.51
341.7
269.03
191.03
144.04
- -
190.51
- -
Basic EPS, GAAP
33.53
-11.79
-78.29
-26.5
-19.84
5.35
-4.41
29.25
1.64
-47.93
-40.59
- -
14.42
- -
Free Cash Flow per Basic Share
-78.98
-86.04
-9.82
-51.2
-6.4
-20.54
-9.71
-76.9
-49.94
-5.86
-4.73
- -
-1.87
- -
Dividend per Share
11.29
7.44
0.02
0.01
- -
- -
- -
- -
5.01
- -
- -
- -
- -
- -
Book Value per Share
220.22
202.47
163.37
162.63
142.69
158.66
163.87
237.78
235.68
188.99
149.93
- -
148.94
143.81
Tangible Book Value per Share
216.41
199.62
163.29
162.53
142.62
158.51
162.95
231.95
220.49
176.51
144.92
- -
147.69
139.79
Basic Weighted Avg Shares
18
18
20
21
23
24
26
27
28
28
28
27
27
28
Sales/Revenue/Turnover
3,922
5,143
4,458
3,847
3,641
4,381
5,067
9,299
7,434
5,278
3,980
- -
5,217
- -
Operating Margin (%)
-22.73
-6.23
-16.55
-11.45
-10.59
3.74
-1.63
9.63
2.05
-21.08
-24.03
- -
3.86
- -
Depreciation Expense
224
292
292
104
83
86
122
374
535
641
409
- -
208
- -
Net Income, GAAP
612
-215
-1,582
-555
-458
130
-114
796
45
-1,324
-1,121
- -
395
- -
Effective Tax Rate (%)
40.03
- -
- -
- -
- -
6.4
- -
- -
72.92
- -
- -
- -
- -
- -
Profit Margin (%)
15.6
-4.18
-35.48
-14.43
-12.57
2.97
-2.26
8.56
0.61
-25.09
-28.18
- -
7.57
- -
Working Capital
3,403
3,320
3,386
3,650
2,977
3,413
3,488
5,226
4,772
3,865
2,651
- -
2,622
2,568
LT Debt
666
736
618
628
386
233
326
1,285
2,672
2,522
290
- -
298
252
Total Equity
4,325
4,035
3,432
3,751
3,291
3,977
4,321
6,579
6,512
5,222
4,143
- -
4,090
3,974
Return on Invested Capital (%)
-6.58
- -
- -
- -
- -
3.23
- -
- -
0.39
- -
- -
- -
- -
- -
Return on Capital (%)
-7.26
- -
- -
- -
- -
2.95
- -
- -
0.54
- -
- -
- -
- -
- -
Return on Common Equity (%)
13.69
-5.58
-44.65
-15.55
-13
3.59
-2.75
14.61
0.69
-22.57
-23.95
- -
- -
- -

Capital Structure

JPY

•

in mil. unless spec.
Mar'24
Jun'24
Dec'25
ST Debt
1,084
1,077
975
LT Borrowings
353
290
252
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
5,692
5,250
6,355

Working Capital

JPY

•

in mil. unless spec.
Mar'24
Jun'24
Dec'25
Total Current Assets
4,829
4,610
4,283
Cash, Cash Equivalents & STI
2,050
1,915
1,716
Accounts Receivable, Net
650
650
780
Inventories
1,815
1,695
1,626
Total Current Liabilities
1,815
1,959
1,715
Payables & Accruals
- -
- -
- -
ST Debt
1,084
1,077
975
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,072
940
929
1,039
3,980
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
5,217

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-7.88
-18.45
2.53
-16.78
-40.59
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
14.42

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yu Sugiyama
Full Time Employees
129
Sector
Health technology
Industry
Medical specialties
Address
88 Kamihongou Matsudo CH Japan 271-0064
IPO Date
Feb 1, 2001
Website
pss.co.jp
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Precision System Science Co., Ltd. (7707.T) develops, manufactures, and sells automated systems and instruments for genetic and protein analysis, in vitro diagnostics, and molecular testing; its core offerings include the geneLEAD series of fully automated sample-to-result PCR systems such as geneLEAD VIII, geneLEAD XXIV, geneLEAD XII plus, and ELITe InGenius for real-time nucleic acid extraction, amplification, and result analysis; magLEAD automated nucleic acid extraction systems like magLEAD 4gC, magLEAD 12gC, and magLEAD 12gC LiNK; LecChip series for glycan profiling and research applications; protein purification systems; reagents; plastic consumables; and supporting software for research, development, and practical IVD applications in genetics, proteomics, immunology, and biochemistry. The company operates primarily in Japan with international sales through OEM partnerships and serves biotechnology, medical research, diagnostics, and healthcare sectors targeting laboratories, diagnostic centers, and research institutions. Founded in 1985 and headquartered in Matsudo-shi, Chiba, Japan, it maintains two consolidated subsidiaries and reported consolidated net sales of 3,979 million yen for the fiscal year ended June 30, 2024. Recent developments include a five-year OEM supply agreement with ELITechGroup announced in August 2024; the joint sales launch of geneLEAD XXIV, magLEAD 4gC, and magLEAD 12gC LiNK systems in April 2024; divestiture of subsidiary Universal Bio Research Co., Ltd. to Shuji Tajima for 60 million yen in August 2024; and a revision of its distribution agreement with DiagCor Life Science Ltd. in March 2025.